DE602007013036D1 - Cyclopropyl-annelierte indolobenzazepine als hcv-ns5b-inhibitoren - Google Patents
Cyclopropyl-annelierte indolobenzazepine als hcv-ns5b-inhibitorenInfo
- Publication number
- DE602007013036D1 DE602007013036D1 DE602007013036T DE602007013036T DE602007013036D1 DE 602007013036 D1 DE602007013036 D1 DE 602007013036D1 DE 602007013036 T DE602007013036 T DE 602007013036T DE 602007013036 T DE602007013036 T DE 602007013036T DE 602007013036 D1 DE602007013036 D1 DE 602007013036D1
- Authority
- DE
- Germany
- Prior art keywords
- indolobenzazepine
- annulated
- cyclopropyl
- hcv ns5b
- ns5b inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80112506P | 2006-05-17 | 2006-05-17 | |
US80200506P | 2006-05-19 | 2006-05-19 | |
US85208406P | 2006-10-16 | 2006-10-16 | |
US89475707P | 2007-03-14 | 2007-03-14 | |
PCT/US2007/068209 WO2007136982A1 (en) | 2006-05-17 | 2007-05-04 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602007013036D1 true DE602007013036D1 (de) | 2011-04-21 |
Family
ID=38512732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602007013036T Active DE602007013036D1 (de) | 2006-05-17 | 2007-05-04 | Cyclopropyl-annelierte indolobenzazepine als hcv-ns5b-inhibitoren |
Country Status (25)
Country | Link |
---|---|
US (1) | US7456166B2 (de) |
EP (1) | EP2024375B1 (de) |
JP (1) | JP5284952B2 (de) |
KR (1) | KR101417145B1 (de) |
AR (1) | AR061008A1 (de) |
AT (1) | ATE501156T1 (de) |
AU (1) | AU2007253998B2 (de) |
BR (1) | BRPI0711821A2 (de) |
CA (1) | CA2651690C (de) |
CY (1) | CY1111526T1 (de) |
DE (1) | DE602007013036D1 (de) |
DK (1) | DK2024375T3 (de) |
EA (1) | EA015286B1 (de) |
HK (1) | HK1122814A1 (de) |
HR (1) | HRP20110194T1 (de) |
IL (1) | IL195025A (de) |
MX (1) | MX2008014435A (de) |
NO (1) | NO341663B1 (de) |
NZ (1) | NZ572555A (de) |
PE (1) | PE20080070A1 (de) |
PL (1) | PL2024375T3 (de) |
SI (1) | SI2024375T1 (de) |
TW (1) | TWI401244B (de) |
WO (1) | WO2007136982A1 (de) |
ZA (1) | ZA200809548B (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005049622A1 (ja) * | 2003-11-19 | 2007-06-07 | 日本たばこ産業株式会社 | 5−5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途 |
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
DE602007006796D1 (de) * | 2006-05-25 | 2010-07-08 | Bristol Myers Squibb Co | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer |
US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7541352B2 (en) * | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) * | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
CN101679437B (zh) | 2007-03-13 | 2013-04-17 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
CN101815533A (zh) | 2007-05-04 | 2010-08-25 | 弗特克斯药品有限公司 | 用于治疗hcv感染的组合治疗 |
US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
SI2209789T1 (sl) * | 2007-11-20 | 2012-06-29 | Bristol Myers Squibb Co | Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji |
US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
AU2008338273B2 (en) | 2007-12-19 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
BRPI0821836A2 (pt) * | 2007-12-24 | 2015-06-16 | Tibotec Pharm Ltd | Indóis macrocíclicos como inibidores do vírus da hepatite c |
EP2280978B1 (de) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidinkondensierte indolobenzadiazepine als hcv-ns5b-inhibitoren |
US8178523B2 (en) * | 2008-03-27 | 2012-05-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP2011515496A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンhcvns5b阻害剤 |
US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
SG172848A1 (en) | 2009-01-07 | 2011-08-29 | Scynexis Inc | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
RU2559886C2 (ru) | 2010-06-24 | 2015-08-20 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | ПОЛУЧЕНИЕ 13-ЦИКЛОГЕКСИЛ-3-МЕТОКСИ-6-[МЕТИЛ-(2-{2-[МЕТИЛ-(СУЛЬФАМОИЛ)-АМИНО]-ЭТОКСИ}-ЭТИЛ)-КАРБАМОИЛ]-7Н-ИНДОЛО-[2,1-α]-[2]-БЕНЗАЗЕПИН-10-КАРБОНОВОЙ КИСЛОТЫ |
US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
EP2658859A4 (de) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | Makrocyclische hepatitis-c-serinprotease-hemmer |
SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
SG11201500157TA (en) | 2012-07-18 | 2015-03-30 | Bristol Myers Squibbholdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
EP3089757A1 (de) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Feste antivirale darreichungsformen |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US753137A (en) * | 1904-02-23 | Dust-pan | ||
US752354A (en) * | 1904-02-16 | Composition post | ||
US756203A (en) * | 1903-11-14 | 1904-04-05 | Oliver E Barthel | Muffler. |
SI1719773T1 (sl) | 2004-02-24 | 2009-08-31 | Japan Tobacco Inc | Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV |
US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
DE502005002697D1 (de) | 2004-10-13 | 2008-03-13 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
WO2006046039A2 (en) * | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
GB0608928D0 (en) * | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
-
2007
- 2007-05-03 US US11/743,921 patent/US7456166B2/en not_active Expired - Fee Related
- 2007-05-04 SI SI200730612T patent/SI2024375T1/sl unknown
- 2007-05-04 KR KR1020087027866A patent/KR101417145B1/ko active IP Right Grant
- 2007-05-04 MX MX2008014435A patent/MX2008014435A/es active IP Right Grant
- 2007-05-04 PL PL07761873T patent/PL2024375T3/pl unknown
- 2007-05-04 BR BRPI0711821-0A patent/BRPI0711821A2/pt not_active IP Right Cessation
- 2007-05-04 EA EA200802346A patent/EA015286B1/ru not_active IP Right Cessation
- 2007-05-04 AT AT07761873T patent/ATE501156T1/de active
- 2007-05-04 AU AU2007253998A patent/AU2007253998B2/en not_active Ceased
- 2007-05-04 DE DE602007013036T patent/DE602007013036D1/de active Active
- 2007-05-04 WO PCT/US2007/068209 patent/WO2007136982A1/en active Application Filing
- 2007-05-04 NZ NZ572555A patent/NZ572555A/en unknown
- 2007-05-04 JP JP2009511151A patent/JP5284952B2/ja active Active
- 2007-05-04 EP EP07761873A patent/EP2024375B1/de active Active
- 2007-05-04 DK DK07761873.4T patent/DK2024375T3/da active
- 2007-05-04 CA CA2651690A patent/CA2651690C/en not_active Expired - Fee Related
- 2007-05-15 PE PE2007000585A patent/PE20080070A1/es active IP Right Grant
- 2007-05-17 AR ARP070102138A patent/AR061008A1/es active IP Right Grant
- 2007-05-17 TW TW096117512A patent/TWI401244B/zh not_active IP Right Cessation
-
2008
- 2008-10-30 IL IL195025A patent/IL195025A/en not_active IP Right Cessation
- 2008-11-04 NO NO20084637A patent/NO341663B1/no not_active IP Right Cessation
- 2008-11-07 ZA ZA2008/09548A patent/ZA200809548B/en unknown
-
2009
- 2009-03-31 HK HK09103021.8A patent/HK1122814A1/xx not_active IP Right Cessation
-
2011
- 2011-03-16 HR HR20110194T patent/HRP20110194T1/hr unknown
- 2011-06-03 CY CY20111100539T patent/CY1111526T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE501156T1 (de) | Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren | |
DK2373172T3 (da) | Hcv-ns5a-hæmmere | |
BRPI0923184A2 (pt) | inibidores de hcv ns3 protease | |
CY2017005I1 (el) | Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv | |
ATE493428T1 (de) | Hcv-nukleosidinhibitor | |
BRPI0807087A2 (pt) | Inibidores de hcv macrocíclicos substituídos de pirimidina | |
DK1924593T3 (da) | HCV NS3-proteaseinhibitorer | |
CY2015004I2 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
BRPI0807887A2 (pt) | Compostos macrocíclicos como inibidores de hcv ns3 protease. | |
IL198401A0 (en) | Hcv ns3 protease inhibitors | |
EP2083844A4 (de) | Inhibitoren der hcv-ns3-protease | |
EP2079480A4 (de) | Hcv-ns3 -proteasehemmer | |
EP2079479A4 (de) | Inhibitoren der hcv-ns3-protease | |
EP2076278A4 (de) | Hcv-ns3 -proteasehemmer | |
EP2271345A4 (de) | Hcv-ns3 -proteasehemmer | |
ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
ATE543816T1 (de) | Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase | |
ATE510825T1 (de) | Acylaminopyrazole als fgfr-inhibitoren | |
ZA201104911B (en) | Inhibitors of hcv ns5a | |
ATE549333T1 (de) | Neue sulfonylpyrrole als hdac-inhibitoren | |
ATE467623T1 (de) | Diazepan-acetamidderivate als selektive 11-hsd1- hemmer | |
ATE452132T1 (de) | Benzimidazolthiophenverbindungen als plk- inhibitoren | |
ATE495153T1 (de) | Arylsulfonylpyrrolidine als 5-ht6-inhibitoren | |
ZA200902475B (en) | HCV NS3 Protease Inhibitors |